Pfizer inks deal with startup Adapsyn to search microbes for novel compounds
Pfizer is recruiting Canadian upstart Adapsyn Bioscience to dig for novel compounds by scraping and crunching genomic and metabolomic data from microbes. The research collaboration came with some upfront cash and up to $162 million in biobucks down the road.
The small biotech, launched in 2016, says it uses AI and machine learning to find novel and mechanistically diverse small molecules from human and environmental microbes.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
